Correction - - Results of the Annual General Meeting held on September 24, 2008
Correction for the announcement made on September 24, 2008. Two paragraphs were truncated from the original announcement.
Dublin, Ireland – September 25, 2008 – Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that at its Annual General Meeting today, all resolutions contained in the notice of meeting were duly passed and the results of the poll are as follows:
| | For* | Against | Withheld** |
| 1. | To elect Mr Matthew Emmens as a Director of the Company | 301,376,910 | | 4,696,170 | | 25,441,808 | |
| 2. | To elect Mr Angus Russell as a Director of the Company | 331,225,599 | | 138,229 | | 151,060 | |
| 3. | To elect Mr Graham Hetherington as a Director of the Company | 331,234,635 | | 127,173 | | 153,080 | |
| 4. | To elect Dr Barry Price as a Director of the Company | 328,858,454 | | 2,501,778 | | 154,656 | |
| 5. | To elect Mr David Kappler as a Director of the Company | 330,945,634 | | 412,470 | | 156,784 | |
| 6. | To elect Dr Jeffrey Leiden as a Director of the Company | 331,221,109 | | 138,828 | | 154,951 | |
| 7. | To elect Mr Patrick Langlois as a Director of the Company | 330,949,493 | | 412,089 | | 153,306 | |
| 8. | To elect Ms Kate Nealon as a Director of the Company | 331,014,606 | | 346,949 | | 153,333 | |
| 9. | To elect Mr David Mott as a Director of the Company | 327,884,774 | | 2,101,928 | | 1,528,186 | |
| 10. | To elect Dr Michael Rosenblatt as a Director of the Company | 331,232,603 | | 126,815 | | 155,470 | |
| 11. | To re-appoint Deloitte & Touche LLP as Auditors of the Company | 327,634,578 | | 1,301,388 | | 2,578,922 | |
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
| 12. | To authorise the Audit, Compliance and Risk Committee to determine the remuneration of the Auditors | 331,225,599 | | 1,470,679 | | 159,584 | |
| 13. | To authorise the allotment of shares | 328,104,104 | | 3,189,130 | | 221,654 | |
| 14. | To authorise the disapplication of pre-emption rights | 329,760,418 | | 1,575,955 | | 178,515 | |
| 15. | To authorise market purchases | 330,598,450 | | 729,745 | | 186,693 | |
| 16. | To change the name of the Company to Shire plc | 331,323,817 | | 31,609 | | 159,462 | |
* These figures include discretionary votes
** A vote “withheld” is not a vote in law and is not counted in the calculation of the votes “for” or “against” a resolution.
Two copies of all resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the UK Listing Authority and will be available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at the Financial Services Authority, 25 The North Colonnade, Canary Wharf, London E14 5HS.
The change of name of the Company to Shire plc is expected to become effective on October 1, 2008, following the registration of the change with Companies Registry in Jersey.
For further information please contact:
| Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
| | Eric Rojas (North America) | +1 484 595 8252 |
| Media | Jessica Mann (Rest of the World) | +44 1256 894 280 |
| | Matthew Cabrey (North America) | +1 484 595 8248 |
| | Jessica Cotrone (North America) | +1 617 613 4640 |
Notes to editors
SHIRE LIMITED
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX
